NEW YORK, Nov. 19 — German genomics firm atugen has signed an evaluation agreement with countrymate Byk Gulden, the company said on Monday
Under the agreement, Byk Gulden, based in Constance, will provide atugen with cancer-associated genetic targets in specific cell lines. Berlin-based atugen will in turn identify biological function of the targets and validate them for potential drug development.
Financial details of the agreement were not disclosed.
Atugen is focused on high throughput target analysis and validation of pharmaceutical targets. Its GeneBloc technology works by inducing small DNA/RNA hybrid molecules to bind to and destroy target mRNA. This specific mRNA loss can then be correlated with functional changes in vivo and in cell-based assays, leading to an understanding of gene function.
Byk Gulden, the pharmaceutical division of ALTANA, specializes in therapeutics for gastrointestinal, respiratory tract, and cardiovascular conditions.